Holen Sie sich die Stockscreener-App
2.60
1.52%
-0.04
Handel nachbörslich:
2.62
0.02
+0.77%
Schlusskurs vom Vortag:
$2.64
Offen:
$2.58
24-Stunden-Volumen:
2,990
Relative Volume:
0.07
Marktkapitalisierung:
$21.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.74M
KGV:
-1.0359
EPS:
-2.51
Netto-Cashflow:
$-18.90M
1W Leistung:
+3.98%
1M Leistung:
-30.29%
6M Leistung:
-14.33%
1J Leistung:
-1.82%
1-Tages-Spanne:
$2.58
$2.62
1-Wochen-Bereich:
$2.45
$2.74
52-Wochen-Spanne:
$2.19
$4.20
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Firmenname
Lisata Therapeutics Inc
Sektor
Branche
Telefon
908-229-2590
Adresse
110 ALLEN ROAD, BASKING RIDGE
Vergleichen Sie LSTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
2.60 | 21.83M | 0 | -20.74M | -18.90M | -2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lisata Therapeutics Inc Aktie (LSTA) Neueste Nachrichten
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference - GlobeNewswire
Lisata Therapeutics CEO to present at 2025 BIO CEO & Investor Conference - Proactive Investors USA
Lisata's Cancer Treatment Pipeline Takes Center Stage at Major Biotech Investor Conference - StockTitan
Lisata completes subject enrolment in multi-cancer trial of certepetide - MSN
Lisata falls after mid-stage data for anticancer agent - MSN
Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMI - Proactive Investors UK
Lisata reports positive early trial results for pancreatic cancer drug By Investing.com - Investing.com Australia
Lisata Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA Trial Results - Proactive Investors USA
Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA trial results - Proactive Investors USA
Lisata Therapeutics and WARPNINE Announce Encouraging - GlobeNewswire
Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trial - Proactive Investors USA
Lisata reports positive early trial results for pancreatic cancer drug - Investing.com India
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a - The Bakersfield Californian
Lisata's Certepetide Shows Promising Results in Pancreatic Cancer Trial, 63% Response Rate - StockTitan
Lisata Therapeutics Shares Tumble After Pancreatic Cancer Treatment Results - MarketWatch
Stock market news: Star Fashion Culture Holdings -78.42%, Lisata Therapeutics -33.08% among biggest losers in early trading - Business Upturn
Stock market today: Star Fashion Culture Holdings -79.05%, Lisata Therapeutics -23.34% among biggest losers in early trading - Business Upturn
Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trial - Proactive financial news
Lisata stock falls after cancer drug data (LSTA:NASDAQ) - Seeking Alpha
Lisata Therapeutics Reports Encouraging Preliminary Cohort - GlobeNewswire
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 - The Bakersfield Californian
Lisata's Certepetide Shows 31% Better Survival in Pancreatic Cancer Trial Data - StockTitan
First Berlin sets Lisata stock Buy rating on innovative therapies By Investing.com - Investing.com Australia
First Berlin sets Lisata stock Buy rating on innovative therapies - MSN
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit - GlobeNewswire
Lisata Therapeutics CEO to Present at 2025 Sequire Investor Summit in Puerto Rico - StockTitan
US Penny Stocks To Watch In January 2025 - Yahoo Finance
Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus - MSN
Lisata Therapeutics (NASDAQ:LSTA) Trading Up 1.4% – Still a Buy? - Defense World
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation - Simply Wall St
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors UK
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases | NASDAQ:CADL - Proactive Investors UK
Lisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnership - Proactive Investors USA
Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial - Yahoo Finance
Lisata Therapeutics, Inc. Announces Completion of Patient Enrollment in All Three Cohorts of the Phase 1b/2a Cendifox Trial - Marketscreener.com
Lisata Therapeutics completes patient enrollment for CENDIFOX trial - Proactive Investors Australia
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial - GlobeNewswire
Lisata Therapeutics Hits Major Milestone in Cancer Trial: Full Enrollment Complete for CENDIFOX Study - StockTitan
Lisata Therapeutics completes patient enrollment for solid tumor cancer trial - Proactive Investors USA
Neostem stock hits 52-week low at $2.41 amid market fluctuations - Investing.com Canada
Neostem stock hits 52-week low at $2.41 amid market fluctuations By Investing.com - Investing.com South Africa
Lisata Therapeutics and Kuva Labs announce global license agreement for solid tumor imaging - MSN
Lisata and Kuva Labs partner for MR imaging agents to detect cancer - Yahoo Finance
Lisata Therapeutics inks major deal with Kuva Labs - Investing.com
Lisata Therapeutics inks major deal with Kuva Labs By Investing.com - Investing.com Canada
Lisata Therapeutics Enters Global Collaboration with Kuva Labs to Advance Tumor Imaging Technology - Proactive Investors UK
Lisata Therapeutics, Inc. and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging - Marketscreener.com
Finanzdaten der Lisata Therapeutics Inc-Aktie (LSTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):